Christina Lindahl - Concepedia

Author

Christina Lindahl

Aarhus University Hospital

Also Known As

C Lindahl, C. Lindahl, Christina Lindahl, Lindahl, C.

Publications

935

Citations

H-Index

Concepts

All Affiliations

Aarhus University Hospital Oslo University Hospital Helsinki University Hospital Pfizer (Sweden)Pfizer (United States)

About

Christina Lindahl is an author at Aarhus University Hospital specializing in cardiovascular disease, medicine, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	341
2	Public Health	5	5	662
3	Health Sciences	1	1	54
4	Social Sciences	1	1	46
5	Diabetes	1	1	151

Christina Lindahl

Publications

932

Citations

H-Index

Page 1

	Year	Citations
High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk Wim A. van der Steeg, Ingar Holme, S. Matthijs Boekholdt, Journal of the American College of Cardiology Metabolic SyndromeHigh-density Lipoprotein CholesterolCardiovascular EpidemiologyCardiovascular DiseaseCardiovascular Risk	2008	377
Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease Ingar Holme, Rana Fayyad, Sonal Bhatia, The American Journal of Cardiology Metabolic SyndromeNew TargetsCardiovascular DiseaseHealth PolicyMedicine	2009	151
Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy Matti J. Tikkanen, Michael Szarek, Rana Fayyad, Journal of the American College of Cardiology Cardiovascular EpidemiologyCardiovascular DiseaseDyslipidemiaPublic HealthAtherosclerosis	2009	64
Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study) Matti J. Tikkanen, Ingar Holme, Nilo B. Cater, The American Journal of Cardiology Versus ≥65Incremental DecreaseLipid DisorderCardiovascular DiseaseHyperlipidemia	2009	55
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study Terje R. Pedersen, John J.P. Kastelein, Anders Olsson, The American Journal of Cardiology ObesityMetabolic SyndromeLipid AnalysisLipid DisorderBody Composition	2004	54
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL) Ingar Holme, Nilo B. Cater, John J.P. Kastelein, Annals of Medicine	2008	50
A holistic model for landscape ecology in practice: the Swedish survey and management of ancient meadows and pastures Margareta Ihse, Christina Lindahl Landscape and Urban Planning Landscape ArchaeologyLand UseLandscape PlanningGeographyNatural Resource Management	2000	46
Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial) Terje R. Pedersen, Nilo B. Cater, John J.P. Kastelein, The American Journal of Cardiology Cardiovascular EventsCardiovascular DiseaseCoronary Artery DiseaseCardiovascular PharmacologyAcute Myocardial Infarction	2010	39
Comparative Effect of Atorvastatin (80 mg) Versus Simvastatin (20 to 40 mg) in Preventing Hospitalizations for Heart Failure in Patients With Previous Myocardial Infarction Timo Strandberg, Ingar Holme, John J.P. Kastelein, The American Journal of Cardiology Heart FailureCardiovascular DiseaseComparative EffectVersus SimvastatinCardiovascular Pharmacology	2009	27
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial Ingar Holme, Rana Fayyad, J.J.P. Kastelein, Journal of Internal Medicine	2009	25

Page 1